A fibrosis molekuláris pathogenezise

Szűcs Gabriella

Debreceni Egyetem

ÁOK Reumatológiai Tanszék
KK Reumatológiai és Immunológiai Klinika

Sejtek közötti és sejten belüli interakciók szerepe az immunválasz kialakításában és szabályozásában
PhD kurzus, SE, Reumatológiai és Klinikai Immunológiai Tanszék
2025. április 3-4.



Timeline of the milestones in the investigation of fibrosis over the past 300 years

Adv. Sci. **2025**, 12, 2410416

FIBROSIS: FROM MECHANISMS TO MEDICINES

Henderson NC et al. Nature. 2020 November ; 587(7835): 555–566.



Az ipari világ halálozásának 45%-a

FIBROSIS: FROM MECHANISMS TO MEDICINES

Henderson NC et al. Nature. 2020 November ; 587(7835): 555–566.

Fibrosis, secondary to age-associated chronic low-grade inflammation (inflammaging)

Fibrotikus szövet kialakulása – sérülés utáni normál repair

extracellular matrix (collagen, fibronectin stb) accumulatio

Pl. bőrben a fascia fibroblastok + a környező egységek (erek, macrophagok, perifériás erek)

↓

Gyógyulás



Funkcionális fibroblast heterogenitás és plaszticitás

Senescence and tissue fibrosis: opportunities for therapeutic targeting



Figure 1. The 12 hallmarks of aging and targeting cellular senescence as an emerging novel therapeutic strategy for fibrosis

Trends in Molecular Medicine, December 2024, Vol. 30, No. 12

Senescence and tissue fibrosis: opportunities for therapeutic targeting



Figure 1. The 12 hallmarks of aging and targeting cellular senescence as an emerging novel therapeutic strategy for fibrosis

Divergens citokin útvonalak vezérlik a fibrosist



Macrophag - fibroblast cross-talk

+ microbiome - TLR

Henderson NC et al. Nature. 2020 November ; 587(7835): 555–566.



Macrophag - fibroblast cross-talk

The NLRP3 inflammasome in fibrosis and aging: The known unknowns





ASC: apoptosis-associated speck-like protein

Fig. 1. Regulatory mechanism of the NLRP3 inflammasome.

FIBROSIS: FROM MECHANISMS TO MEDICINES

Henderson NC et al. Nature. 2020 November ; 587(7835): 555–566.



Szisztémás sclerosis
IgG4-related betegség

Az ipari világ halálozásának 45%-a

Inflammation and immunity in IPF pathogenesis and treatment

Heukels P et al. Respiratory Medicine 147 (2019) 79–91.

Incidencia: 3-9/100 000
>65 év: 94/100 000,
prevalencia 494/100 000

Repetitív alveolaris epithelialis sérülés

+

Repair mechanizmusok diszregulációja

+

fibroblast diszfunkció

↓

fibrosis



Genetikai vizsgálatok vizsgálatok:
***FAM13A* (4q22), *DSP* (6p24), *OBFC1* (10q24)**
WNT, TGF, NOTCH, sonic hedgehog (SHH)
***TOLLIP (*Toll-interacting protein), the inhibitory protein of the Toll-like receptor (TLR)**
DRB1*15:01* and *DQB1*06:02
MUC5B gén

Az ILD klasszifikációja



Am J Respir Crit Care Med Vol 205, Iss 9, pp e18–e47, May 1, 2022



Eur Respir J 2023; 61: 2103187


Genetic factors
Epigenetic factors
Environmental factors
Triggers
Smoking
Aging
Alveolar epithelial cells damage
Imbalance in lung tissue microenvironment, disturbance of cellular interactions.
Expansion of fibroproductive cell populations
Conversion fibroblasts into myofibroblasts
Abnormal deposition of extracellular matrix
Tissue fibrosis - IPF


A
B
C





Figure 1. General scenarios of lung inflammation development: variants and outcomes.

Int. J. Mol. Sci. 2022, 23, 14959. https://doi.org/10.3390/ijms232314959

Fibrocyta – myofibroblast átalakulás



Figure 2. Evolution of fibrocyte to myofibroblast—main effector cell in pulmonary fibrosis development.

Szignál-transzdukció folyamata



Figure 3. Overview of particular signaling pathways regulating pulmonary fibrosis development.

Int. J. Mol. Sci. 2022, 23, 14959. https://doi.org/10.3390/ijms232314959

Innate immunrendszer szerepe

Inflammation and immunity in IPF pathogenesis and treatment

Heukels P et al. Respiratory Medicine 147 (2019) 79–91.



Kapcsolat az adaptív immunrendszerrel

Fig. 1. Schematic overview of the role of the innate immune system in IPF pathogenesis. Abbreviations: EMT = epithelial–mesenchymal transition, Il

Adaptív immunrendszer szerepe

Inflammation and immunity in IPF pathogenesis and treatment

Heukels P et al. Respiratory Medicine 147 (2019) 79–91.



Fig. 2. Schematic overview of the role of the adaptive immune system in IPF pathogenesis. * also known as B lymphocyte stimulator (BLy

Asthma és fibrosis



Principal pathophysiological components of airway remodeling emergence in allergic asthma.

•. 2023 Nov 7;24(22):16042. doi: 10.3390/ijms242216042.



Asthma and Post-Asthmatic Fibrosis

Biomedicines **2022**, 10, 17.


Máj
Jobb lebeny
Epehólyag
Epehólyag kivezető
Bal lebeny
Bal májvezeték
Jobb májvezeték
Közös májvezeték
Epevezeték



Complex mechanisms driving the pathological development of NAFLD.

Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits

Peiseler M et al. Journal of Hepatology 2022 vol. 77 j 1136–1160.

Előfordulás: 6-35%/populáció



Fig. 1. Triggers of inflammation in NAFLD. Intra- and extrahepatic factors trigger inflammation in NAFLD. Hypercaloric diet, obesity, lifestyle, and genetic risk

Metabolic reprogramming in liver fibrosis



Figure 1. General mechanisms of liver fibrosis and main metabolic adaptations in macrophages, lymphocytes, and activated hepatic stellate cells

Metabolic reprogramming in liver fibrosis



Figure 1. General mechanisms of liver fibrosis and main metabolic adaptations in macrophages, lymphocytes, and activated hepatic stellate cells



Figure 3. Metabolic reprogramming in fibrogenic hepatic stellate cell activation



Figure 2. Metabolic reprogramming in hepatic macrophage activation during liver fibrogenesis


Anti-diabetic and anti-obese therapies
•GLP1R agonists
•GLP1R/GIPR agonists
•GLP1R/GCGR agonists
•GCGR/GIPR/GLP1R agonists
•PPAR agonists
•SGLT2 inhibitors
Metabolism Lipotoxicity
•FXR agonists
•PPAR agonists
•THR-β agnonists
•ACC inhibitors
•FASN inhibitors
•SCD1inhibitors
•DGAT1/2 inhibitors
•MPC inhibitors
•AMPK activators
•FGF19 analogues
•FGF21 analogues
•ACLY inhibitors
•LXR modulators
Anti-inflammatory strategies
•ASK1 inhibitors
•CCR2/5 inhibitors
Insulin resistance
Inflammasome secretion
Fibrogenesis
Liver cirrhosis/ HCC
Lipid accumulation
ER stress
HSC activation
Mitochondrion dysfunction
NAFLD/ NASH
Liver steatosis
Others
•AOC3 inhibitors
•Pan-PDE inhibitors
•A3AR agonists
Extrahepatic tissues
•PPAR agonists
•GLP1R agonists
•GLP1R/GIPR agonists
•SGLT2 inhibitors

Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

Begoña López[1,2,4], Susana Ravassa[1,2,4], María U. Moreno[1,2,4], Gorka San José[1,2], Javier Beaumont[1,2], Arantxa González[1,2]✉ and Javier Díez[1,2,3]✉

Box 1 | **Conditions associated with diffuse myocardial fibrosis**

Ischaemic heart disease
- Coronary artery disease[6]
- Alterations of the coronary microcirculation caused by hypertension[7] or diabetes mellitus[8]

Cardiac pressure overload
- Systemic arterial hypertension[9]
- Aortic stenosis[10]
- Coarctation of the aorta[11]
- Pulmonary arterial hypertension[a,12]

Cardiac volume overload
- Obesity[a,13]
- Aortic regurgitation[14]
- Mitral regurgitation[a,15]

Cardiac inflammation
- Myocarditis[16]
- Sarcoidosis[a,17]

Genetic cardiac diseases
- Hypertrophic cardiomyopathy[18]

Cardiac metabolic alterations
- Obesity[a,13]
- Diabetes mellitus[19]
- Chronic kidney disease[a,20]

Infiltrative cardiac alterations
- Amyloidosis[21]

Cardiac storage diseases
- Anderson–Fabry disease[a,22]

Congenital heart diseases
- Tetralogy of Fallot[23]
- Ebstein anomaly[a,24]
- Transposition of the great arteries[a,25]

Other conditions
- Ageing[26]
- Non-ischaemic dilated cardiomyopathy[27]
- Atrial fibrillation-mediated cardiomyopathy[28]
- Exposure to pharmacological cardiotoxic agents[29]

[a]Conditions in which diffuse myocardial fibrosis was identified by cardiovascular MRI instead of endomyocardial biopsy, which was performed in the other conditions.

Nature Reviews Cardiology **volume 18**, pages479–498 (2021)

Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

Begoña López[1,2,4], Susana Ravassa[1,2,4], María U. Moreno[1,2,4], Gorka San José[1,2], Javier Beaumont[1,2], Arantxa González[1,2]✉ and Javier Díez[1,2,3]✉

Box 1 | **Conditions associated with diffuse myocardial fibrosis**

Ischaemic heart disease
- Coronary artery disease[6]
- Alterations of the coronary microcirculation caused by hypertension[7] or diabetes mellitus[8]

Cardiac pressure overload
- Systemic arterial hypertension[9]
- Aortic stenosis[10]
- Coarctation of the aorta[11]
- Pulmonary arterial hypertension[a,12]

Cardiac volume overload
- Obesity[a,13]
- Aortic regurgitation[14]
- Mitral regurgitation[a,15]

Cardiac inflammation
- Myocarditis[16]
- Sarcoidosis[a,17]

Genetic cardiac diseases
- Hypertrophic cardiomyopathy[18]

Cardiac metabolic alterations
- Obesity[a,13]
- Diabetes mellitus[19]
- Chronic kidney disease[a,20]

Infiltrative cardiac alterations
- Amyloidosis[21]

Cardiac storage diseases
- Anderson–Fabry disease[a,22]

Congenital heart diseases
- Tetralogy of Fallot[23]
- Ebstein anomaly[a,24]
- Transposition of the great arteries[a,25]

Other conditions
- Ageing[26]
- Non-ischaemic dilated cardiomyopathy[27]
- Atrial fibrillation-mediated cardiomyopathy[28]
- Exposure to pharmacological cardiotoxic agents[29]

[a]Conditions in which diffuse myocardial fibrosis was identified by cardiovascular MRI instead of endomyocardial biopsy, which was performed in the other conditions.



Fig. 1 | **Pathogenesis and consequences of diffuse myocardial fibrosis.** In response to cardiac injury,

Nature Reviews Cardiology **volume 18**, pages479–498 (2021)

Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

Begoña López[1,2,4], Susana Ravassa[1,2,4], María U. Moreno[1,2,4], Gorka San José[1,2], Javier Beaumont[1,2], Arantxa González[1,2]✉ and Javier Díez[1,2,3]✉



Fig. 3 | **Major signalling pathways involved in the activation of cardiac fibroblasts.** In response to increased



Nature Reviews Cardiology **volume 18**, pages479–498 (2021)

Myocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact

Endomyocardial biopsy (EMB)



Reactive interstitial fibrosis | Focal replacement fibrosis | Perivascular fibrosis

Cardiac magnetic resonance (CMR) imaging



Late gadolinium enhancement (LGE) | Native T1 mapping | Post-contrast T1 mapping

Biomarkers of cardiac fibrosis

Endomyocardial biopsy (EMB)

Pro
- Direct and specific assessment of myocardial collagen

Contra
- Invasive procedure
- Vulnerable to sampling bias
- Screening is logistically challenching

Cardiac MRI or CT

Pro
- Repeatable, non-invasive procedure
- Whole-heart visualisation

Contra
- Low resolution (0.5 - 2.0 mm)
- Limited ability to discriminate tissues
- Mostly detects focal fibrosis



Circulating biomarkers

Pro
- Easy to asess and up-scale
- Inexpensive, reproducible
- Operator independent

Contra
- Not cardiac specific

Myocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact



Matrix Biology 134 (2024) 1–22

Table 3 | **Novel therapies potentially applicable to reverse diffuse myocardial fibrosis**

Target	Therapeutic strategy	Study stage	Status	Ref.
TGFβ1 signalling	Inhibiting connective tissue growth factor activity with the monoclonal antibody pamrevlumab	Phase II trial in patients with idiopathic pulmonary fibrosis	Completed	234
		Phase III trial in patients with idiopathic pulmonary fibrosis	Ongoing	235
Non-coding RNAs	Inhibiting miR-21 with RG-012	Phase I trials in patients with Alport syndrome	Completed	241
		Phase II trials in patients with Alport syndrome	Ongoing	242
	Mimicking miR-29a with remlarsen	Phase I trial in healthy volunteers	Completed	245
		Phase II trial in patients with cutaneous fibrosis	Ongoing	246
Metabolic pathways	Omega-3 fatty acid supplementation	Phase III clinical trial in patients with myocardial infarction	Completed	248
Extracellular collagen processing	LOXL2 inhibition with simtuzumab	Phase II clinical trial in patients with idiopathic pulmonary fibrosis	Completed	254
	Matrix metalloproteinase inhibition with low-dose doxycycline	Phase II clinical trials in patients with acute myocardial infarction and heart failure	Completed	256
		Phase II trial in patients with myocardial infarction	Ongoing	257
Inflammation	Therapy with modified citrus pectin (a galectin 3 inhibitor)	Phase I trial in patients with chronic kidney disease	Ongoing	259
	Therapy with BLD-2660 (a calpain inhibitor)	Phase IIa trial in patients with idiopathic pulmonary fibrosis	Ongoing	260
	Therapy with sodium thiosulfate (a hydrogen sulfide-releasing agent)	Phase II trial in patients with myocardial infarction	Ongoing	262

LOXL2, lysyl oxidase homologue 2; TGFβ1, transforming growth factor-β1.

Nature Reviews Cardiology **volume 18**, pages479–498 (2021)

Human Kidney Anatomy



Kidney fibrosis: from mechanisms to therapeutic medicines



Histone modification and DNA methylation in kidney fibrosis. Suppression of antifibrotic genes



Figure 2. Cellular crosstalk driving kidney fibrosis, and potential intervention points. Proximal tubular epithelial cells (PTCs) are the major cellular component of the

Szisztémás sclerosis

„scleroderma”: „sclero” (kemény) + „derma” (bőr)

Patogenezis



Raynaud tünet

Vazokonstrikció ↑

A simaizomsejtek α-2 adrenoreceptorok reaktivitása ↑

A digitalis artériák hideghatásra, vagy emocionális stresszre bekövetkező kóros válaszreakciója, fokozott vasokonstrikciója

Endothel sérülés

Sejtek közötti adhézió, tight junction fellazulása

Idegrostok (szimpatikus és szenzoros)

Simaizomsejtek

Endotheliális sejtek

Endothelin-1 ↑

PDGF receptor elleni antitestek

Oxidatív stressz

Endothel sejtek elleni antitestek



Vazodilatáció ↓

A szenzoros afferens rostokból származó vazodilatator neuropeptidek (pl. CGRP) szintje ↓

NO ↓

Thrombocyta aktiváció/aggregáció ↑

Fibrinolysis ↓

Thrombin ↓

Vvt deformálódás ↓

Viszkozitás ↑

Fibrosis

Csökkent véráramlás/ prokoaguláns állapot

Contributions of Immune Cells and Stromal Cells to the Pathogenesis of Systemic Sclerosis: Recent Insights

Bingying Dai et al. 2022. Front. Pharmacol. 13:826839.



The role of innate immune cells including monocytes, macrophages, and dendritic cells in the fibrosis in SSc.

Contributions of Immune Cells and Stromal Cells to the Pathogenesis of Systemic Sclerosis: Recent Insights

Bingying Dai et al. 2022. Front. Pharmacol. 13:826839.

Adaptív immunitás

Contribution of T-cell subsets and their cytokines to fibrosis in SSc



Adaptív immunitás

B-sejtek:

- Antitest termelés, citokin szekréció
- IL-6, IFNγ, GM-CSF
- Breg sejtek száma és funkciója is csökken: IL-10
- BAFF: B-sejtek profibrotikus aktivitása nő, fokozódik a citokin szekréció
- Macrophagok M2 polarizációjában, T-sejtek, dendritikus sejtek aktivációjában is részt vesznek: innate-adaptív immunitás összeköttetés



Fibrosis



Gyulladásos mikrokörnyezet

+

Szöveti sérülés, hypoxia, stressz



Kóros fibrosis: fibroblast-myofibroblast (α-simaizom aktint expresszáló) átalakulás, fibroblast apoptosis csökkenés,autokrin aktiváció miatt túlzott kollagén és ECM termelés

Megvastagodott kollagén rostok: I, III, VII-es típusú kollagén, subcutan zsírszövet csökken, kollagén keresztkötések

TGF-β



- **Fibrosis: központi szerep, ECM termelés fokozása, lebontás gátlása**
- **Forrása: fibroblasztok, miofibroblasztok, T-sejtek, monociták, makrofágok és vérlemezkék**
- **I-es típusú kollagén, I-es típusú plazminogén aktivátor inhibitor, CTGF és α-SMA gén expresszió fokozása**



Szervi érintettségek pathogenezise









IgG4-related disease: an update on pathophysiology and implications for clinical care

Cory A. Perugino[1,2] and John H. Stone[1] ✉





Nature Reviews Rheumatology **volume 16**, pages702–714 (2020)

IgG4-related disease: an update on pathophysiology and implications for clinical care

Cory A. Perugino[1,2] and John H. Stone[1] ✉



Nature Reviews Rheumatology **volume 16**, pages702–714 (2020)

Fibrosissal járó kórképek kezelése

Senescence and tissue fibrosis: opportunities for therapeutic targeting

Trends in Molecular Medicine, December 2024, Vol. 30, No. 12

Table 1. Senescence in fibrosis *in vivo*

Target organ	Disease model	Senotherapeutic agent(s)	Outcomes	Refs
Cardiac fibrosis	Aged INK-ATTAC and C57BL/6J mice	ABT-263 (navitoclax)	Pharmacological or genetic clearance of senescent cells in mice alleviated myocardial hypertrophy and fibrosis	[93]
	Ischemia reperfusion model in C57BL/6J mice	ABT-263 (navitoclax)	Navitoclax reduced senescence and improved cardiac function by attenuating the profibrotic SASP, reducing scar, and enabling increased angiogenesis	[94]
	Human cardiac fibrosis on a chip model	Quercetin, dasatinib	The senolytic drugs led to an improvement in contractile function, reduced passive tension, and downregulated senescence-related gene expression in the tissue	[95]
Renal fibrosis	Renal artery stenosis in INK-ATTAC mice	Quercetin, dasatinib	Both p16-specific and quercetin–dasatinib improved renal function and structure	[96]
	C57BL/6J mice on high fat diet	Quercetin	Improved renal function indices and alleviated fibrosis	[97]
	Aged and/or kidney injury models in C57BL/6J mice	ABT-263 (navitoclax)	ABT-263 treatment resulted in improved functional recovery and reduced fibrosis	[44]
	Lupus nephritis in MRL/lpr mice	Fisetin	Fisetin treatment attenuated kidney fibrosis, reduced SASP expression, and increased tubular epithelial cell proliferation	[98]
Lung fibrosis	Bleomycin lung fibrosis in INK-ATTAC mice	Quercetin, dasatinib	Both p16-specific and quercetin–dasatinib improved renal function and structure	[43]
	Ex vivo fibrotic 3D lung tissue	Quercetin, dasatinib	Pharmacological treatment significantly eliminated senescent markers and the SASP	[99]
	Bleomycin lung fibrosis in C57BL/6J mice	Nintedanib	Nintedanib suppressed senescent cell survival through the JAK2/STAT3 signaling pathway in the lung fibrosis model	[100]
	Intratracheal γ-irradiated IMR90 cells in mice	Digoxin	Digoxin effectively eliminated senescence-induced lung fibrosis	[101]
	Bleomycin and crystalline silica-induced lung fibrosis in mice	ABT-263 (navitoclax)	ABT-263 induced fibroblast apoptosis, decreased fibroblast numbers, and reduced fibrosis	[67,102]
	Bleomycin-induced lung fibrosis in mice	Rapamycin	Rapamycin inhibited pulmonary fibrosis and epithelial–mesenchymal transition in mice	[103]
	Radiation-induced lung fibrosis in C57BL/6 mice	FOXO4-DRI	FOXO4-DRI alleviated pulmonary fibrosis by targeting senescence-like fibroblasts *in vivo*	[104]
	Senescent IMR90 cells-induced lung fibrosis in mice	ABT-263 (navitoclax)	Navitoclax significantly reduced collagen content in fibrotic lungs, comparable with the effect of nintedanib and pirfenidone	[105]
Liver fibrosis	CCl_4- or NASH-induced liver fibrosis in C57BL/6N mice	uPAR-specific CAR T cells	CAR T cells efficiently eliminated senescent cells, reduced fibrosis, and improved liver function in mice	[88]


FIBROSIS
Genetikai háttér
Epigenetikai változások
Környezeti faktorok
Kóros innate és adaptív immunválasz
Gyulladásos folyamat
Fibrosis
TERÁPIA

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies



Adv. Sci. **2025**, *12*, 2410416

Targeting fibrosis: mechanisms and clinical trials



Zhao M et al. Signal Transduction and Targeted Therapy (2022) 7:206

Mechanisms of mesenchymal stem cell (MSC)-based therapy for fibrosis



Adv. Sci. **2025**, *12*, 2410416

ORIGINAL RESEARCH

CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury

Jiawan Wang,* Heng Du,* Wanrun Xie,* Jinmiao Bi,* Hao Zhang, Xu Liu, Yuhan Wang, Shaolong Zhang, Anhua Lei, Chuting He, Hailong Yuan, Jiahe Zhang, Yujing Li, Pengfei Xu, Siqi Liu, Yanan Zhou, Jianghua Shen, Jingdong Wu, Yihong Cai, Chaofan Yang, Zeya Li, Yingxin Liang, Yang Zhao, Jin Zhang, Moshi Song

Circulation Research. 2024;135:1161–1174

Cell

Article

Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis

Cell 187, 4890–4904, September 5, 2024

KÖSZÖNÖM A FIGYELMET!

1879-1940